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was not sufficient to normalize phagocytosis in
asthmatic children
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Background: Corticosteroids are the first-line therapy for asthma; however, the effect of corticosteroids on the
innate immune system remains unclear. This study’s objective was to evaluate the effect of inhaled corticosteroid
therapy (ICT) on phagocytic functions.
Methods: To evaluate the impact of ICT, the phagocytosis of Saccharomyces cerevisiae by blood monocytes and
neutrophils and the production of superoxide anions were assessed before and after three and six months of ICT
treatment in 58 children with persistent asthma and 21 healthy controls.
Results: We showed that the phagocytic capacity of monocytes and neutrophils that occurred via pattern
recognition receptors or was mediated by complement and immunoglobulin receptors in asthmatic children before
treatment was significantly lower than in healthy controls (p<0.05, Mann–Whitney test) and was not influenced by
the severity of the clinical form of the disease. Although there was clinical improvement with treatment, ICT for
6 months was not sufficient to normalize phagocytosis by the phagocytes. Superoxide anion production was also
decreased in the asthmatic children before treatment, and ICT normalized the O- production only for children with
mild persistent asthma when assessed at baseline but caused this function to decrease after stimulation (p<0.05,
Kruskal-Wallis test).
Conclusions: Our data suggest that an immunodeficiency in phagocytes remained even after treatment. However,
this immunodeficiency does not appear to correspond with the clinical evolution of asthma because an
improvement in clinical parameters occurred.
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Asthma is a serious global health problem throughout the
world. An estimated 300 million individuals are affected
by this disease [1], which is the most common chronic
disease of childhood [2].
Corticosteroids are the first-line drugs for asthma ther-
apy and are by far the most effective anti-inflammatory
treatment [3], resulting in marked reductions in asthma
morbidity and mortality [4,5].
The goals of asthma treatment are to control the clin-
ical symptoms for extended periods, prevent asthma* Correspondence: mimjunqueira@unb.br
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distribution, and reproduction in any mediumexacerbations, maintain pulmonary function, and control
airway inflammation [6]. Inhaled corticosteroids (ICS) are
very effective in controlling asthma symptoms in patients
of all ages and severities and may prevent irreversible air-
way changes [4,5,7]. However, corticosteroid treatment
also has several side effects [8] and may influence the
functions of immune system cells [9,10].
Children with asthma have an increased frequency of pul-
monary infections, and it is possible that alterations in the
function of phagocytes, which are engaged in the first line
of defense against pathogens, may play a role in these infec-
tions [11]. Monocyte chemotaxis in vitro is inhibited by
high concentrations of steroids [12]. In addition, corticoste-
roids affect nitric oxide production, total free radical pro-
duction, and nitric oxide synthase activity in the monocytesCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of defective phagocytosis of pathogens in asthma patients
[13]. Phagocytosis by alveolar macrophages is impaired in
children with poorly controlled asthma [11], and oxidative
stress is emerging as a common mechanism that may alter
both macrophage and neutrophil functions [13].
The influence of ICS treatment on phagocyte functions
in asthmatic children remains unclear. Either the treatment
or the disease may influence phagocyte functions directly
or through several cytokines and substances produced as
part of the altered immune response in affected individuals.
Therefore, the objective of this study was to evaluate the
undetermined influence of ICS treatment on the phago-
cytic function of monocytes and neutrophils from asth-
matic children after 3 and 6 months of therapy and to
compare phagocytosis and the production of toxic oxygen
radicals in asthmatic children and healthy control subjects.
This study may shed light on the effects of corticosteroids
on cells of the innate immune system in asthmatic children
and may improve the understanding of the mechanism of
action of this drug. It was showed that the phagocytic cap-
acity of monocytes and neutrophils that occurred via pat-
tern recognition receptors or was mediated by complement
and immunoglobulin receptors in asthmatic children before
treatment was significantly lower than in healthy controls
and inhaled corticosteroid treatment for 6 months was not
sufficient to normalize phagocytosis in asthmatic children.
Methods
Study groups
One author (CLFSM), a pediatric pneumologist, conducted
the clinical evaluation of all control and asthmatic children
and sequentially selected and screened 58 children who
were seen in the pediatric asthma outpatient clinic at Brasilia
University Hospital for enrolment in this study. The children
were placed in the following groups: a group of 58 out-
patient asthmatic children with variable disease severity (27
girls and 31 boys; 7.6 ± 3.4 years) from whom blood was
collected before, at 3 months, and at 6 months of inhaled
corticosteroid therapy. Asthma was classified as mild, mod-
erate, or severe persistent disease by the frequency of the
symptoms, presence of nocturnal asthma, frequency of acute
exacerbations, medications required for control, physical ac-
tivity limitations, or altered pulmonary functioning [14].
Twenty-four (41.3%) asthmatic children had mild asthma,
20 (34.5%) children had moderate asthma and 14 (24.1%)
had severe persistent asthma. A group of 21 healthy children
(12 girls and 9 boys; 10.7 ± 2.10 years) without the disease
and without a personal or familial history of allergy com-
prised the control group. At the time of clinical examination,
peripheral blood was collected to assess phagocytosis and
superoxide anion production.
The exclusion criteria were as follows: children < 2 years
or > 18 years, any other clinically significant pulmonarydisease or other disease, those who presented with any con-
dition that might alter the function of the immune system,
any children taking medication other than asthma treat-
ment, and any children that had previously used inhaled
corticosteroids, or that used oral corticosteroids in the last
6 months.
During the first evaluation, the group of asthmatic
children was assessed for the severity of asthma, asthma
control test (ACT), peak expiratory flow (PEF), and
body mass index (BMI). The ACT was administered to
children aged 4–11 years (7 answers) and >12 years (5
answers). The test was adapted for children < 4 years,
with the mother responding to the questions. The chil-
dren were considered clinically controlled (ACT ≥ 25),
partially controlled (ACT = 20–24) or uncontrolled
(ACT < 20) [15].
The PEF value was recorded as the best of three forced
expirations by means of a peak flow meter and expressed as
the percentage of predicted of normal values for height and
sex values for children ≥ 100 cm. In seven children with
mild persistent asthma (mPA), one child with moderate
persistent asthma (MPA) and three with severe persistent
asthma (SPA) the PEF were not assessed. All these children
younger than 5 years had familial history of asthma. The
thresholds of PEF used to severity evaluation were: mPA
≥80% predicted value, MPA= 60-80% predicted value, and
SPA ≤ 60% predicted value.
BMI was assessed to exclude any possible influence of
child nutritional status on phagocyte functions.
During the second (3 months) and third (6 months)
clinical follow-up visits, the children were assessed with
the ACT, PFE and BMI.
The children were treated with ICS. A long-acting
β2-agonist (LABA) was added when necessary to con-
trol symptoms. All 24 children with mild persistent
asthma (mPA), 10 children <4 years with moderate per-
sistent asthma (MPA) and 5 children < 4 years with se-
vere persistent asthma (SPA) received monotherapy
with 250 μg beclomethasone dipropionate twice day.
Eight children with MPA and three with SPA received
budesonide + formoterol 6/200 μg twice day and 1
children with SPA received 12/400 μg twice day. Two
children with MPA and five children with SPA received
fluticasone propionate + salmeterol 25/125 μg twice
day (Table 1).
Peripheral blood was collected from control and asth-
matic children who had fasted for > 12 hours prior to their
blood being drawn. Hemogram (Cell-dyn 3.700) was auto-
matically assessed.
The Human Research Ethical Committee of the School
of Medicine of the University of Brasilia approved the ex-
perimental protocol (process no. 02/2007).
All parents provided formal informed consent for their
child’s participation in this study.
Table 1 Clinical characteristics of healthy controls and asthmatic children before inhaled corticosteroid therapy










Number 21/78 24/58 (41.3%) 20/58 (34.5%) 14/58 (24.1%)
Gender (boys/girls) 9/12 13/11 12/8 6/8 Chi-square p=0.64
Age (years) (mean±SD) 10.7±2.1 6.32±2.99 9.22±3.33 7.24±3.53 ANOVA* p<0.05
Total leukocytes 7390 9720 8120 8305 Kruskal-Wallis
p=0.05
Neutrophils 3440 4150 3640 4260 Kruskal-Wallis
p=0.66
Monocytes 568 568 536 643 Kruskal-Wallis
p=0.57
Eosinophils 245 460 635 487 ANOVA p=0.003
BMI (Kg/m2) (mean±SD) 43.31±32.1 51.9±34.2 47.4±31.2 63.7±32.5 Kruskal-Wallis
p=0.29
PEF (%) (mean±SD) 86.9±18.6 81.2±17.3 75.6±15.3 65.6±12.0 ANOVA** p<0.05
Treatment***
ICS (%) 23/23 (100%) 10/20 (50%) 05/14 (35.7%)
ICS + LABA (%)
Budesonide + formoterol 0/23 (0%) 08/20 (40%) 04/14 (28.6%)
Fluticasone propionate +
salmeterol
0/23 (0%) 02/20 (10%) 05/14 (35.7%)
BMI Body Mass Index (percentile), PEF Peak Expiratory Flow, mPA mild persistent asthma, MPA moderate persistent asthma, SPA severe persistent asthma,
mPA, MPA, SPA data before treatment. Beclomethasone dipropionate = 250 μg to 500 μg/day; Budesonide + formoterol 6/200 μg or 12/400 μg twice day;
Fluticasone propionate + salmeterol = 25/125 μg to 50/250 μg twice day K-W= Kruskal-Wallis + Dunn’s method; * mPA and SPA < C; ** SPA < C;
*** Treatment followed GINA.
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Phagocytosis of Saccharomyces cerevisiae was adapted
from a previously described technique [16]. Briefly, 40 μL
samples per marked area of heparinized whole peripheral
blood obtained from each subject were placed on dupli-
cate slides containing 8 areas that were each 7-mm in
diameter and incubated in a humidified chamber for
45 min at 37°C. The slides were then rinsed with 0.15 M
phosphate-buffered saline (PBS) (pH 7.2) at 37°C to re-
move non-adherent cells. Adherent cells (12,534±5,050
cells/marked area; 5.63±0.85% monocytes and 93.5±1.08%
neutrophils) (viability > 98%) were incubated with a sus-
pension of 2.5×105 S. cerevisiae in 20 μL Hanks-Tris solu-
tion (Sigma Co., St Louis, MO, USA) (pH 7.2) containing
10% heat-inactivated fetal calf serum (FCS) (Gibco/
Invitrogen, Grand Island, NY, USA) for 30 min in a hu-
midified chamber at 37°C. The slides were then rinsed
with 0.15 M PBS at 37°C to eliminate non-phagocytosed
S. cerevisiae, and the final wash step was performed with
30% FCS in Hanks-Tris solution. The slides were fixed
with methanol and stained with 10% Giemsa stain. The
number of S. cerevisiae that were phagocytosed by either
200 monocytes or 200 neutrophils in individual prepara-
tions was assessed by light microscopy. The phagocytic
index was calculated as the mean number of phagocytosed
S. cerevisiae per phagocytosing monocyte or neutrophilmultiplied by the percentage of these cells engaged in
phagocytosis.
The internalization of particles by phagocytes occurs
via receptors. When phagocytosis occurs via pattern-
recognition receptors, the phagocyte recognizes directly
conserved pattern molecular in the surface of the par-
ticle to be phagocytosed. When phagocytosis is facili-
tated by opsonins, the ingestion occurs via receptors to
components of complement or via receptors to FcIgG.
Saccharomices cerevisiae (Baker’s yeasts) suspensions
were prepared according to a previously described tech-
nique [16] to assess phagocytosis via pattern-recognition
receptors and facilitated by opsonins. Yeasts were used
with or without previous incubation with fresh serum
from the donor. In the former case, yeast cells were con-
sidered sensitized, because they were opsonized by com-
plement molecules and antibodies in serum. These
molecules adhere on yeast surface and will be recog-
nized by their neutrophil and monocyte receptors (CR1,
CR3 and FcR) during the process respective of phagocyt-
osis [16]. Yeast cells that were not pre-incubated with
fresh serum from the donor, but were incubated with
fetal calf serum, were considered as non-sensitized, be-
cause they were non-opsonized and their phagocytosis
occurs via the pattern-recognition receptors (PRRs) of
neutrophils and monocyte [17]. For opsonization, the
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30 min with 10% fresh serum from the donor in Hanks-Tris
solution. The yeast cells that were pre-incubated with
inactivated fetal calf serum were considered non-sensitized,
and their phagocytosis occurred via the pattern-recognition
receptors of phagocytes [17].
Nitro blue tetrazolium slide test
The nitro blue tetrazolium (NBT) test evaluated the
ability to generate toxic oxygen radicals (superoxide
anion/O2
−) that are capable of reducing the compound
NBT to an insoluble form, formazan, which is identi-
fied via optical microscopy as a blue color in the cy-
toplasm of the cell [18]. The amount of reduced NBT
is directly proportional to the amount of oxygen ra-
dicals (O2
−) produced by the phagocytes. After the
phagocytes were adhered, cells from the control and
asthmatic children were incubated with 0.05% NBT
solution in Hanks-Tris solution (Sigma, St Louis, MO,
USA) for 20 min at 37°C in a humidified chamber.
The slides were then washed, fixed with methanol
and stained with a 1.4% safranin and 28.6% glycerol.
The percentage of phagocytes that contained reduced
cytoplasmic NBT was assessed by optical microscopy,Table 2 Clinical characteristics of asthmatic children before, 3











≥25 0/23 (0%) 1/23 (
20-24** 11/23 (47.8%) 19/23 (
<20*** 12/23 (52.2%) 3/23 (1
MPA
≥25 0/20 0%) 1/20
20-24** 2/20 (10%) 7/20
<20*** 18/20 (90%) 12/20
SPA
≥25 0/14 (0%) 0/14
20-24 2/14 (14.3%) 3/14 (2
<20 12/14 (85.7%) 11/14 (7
PEF Peak Expiratory Flow, BMI Body Mass Index (percentile), ACT Asthma Control Te
SPA severe persistent asthma, * 6 m > before ** 3 m and 6 m > before *** 3 m andand the source of the individual preparations was re-
vealed only at the end of the evaluation [18].
Statistical analysis
The data were previously tested with Bartlett’s test for equal
variances and the Kolmogorov–Smirnov test for normality
of distribution. The Mann–Whitney test was used to com-
pare two non-normal samples. The Kruskal-Wallis test,
followed by Dunn’s method, was used to compare multiple
non-normal samples. Spearman’s test was used to evaluate
the correlation between samples. The chi-square test was
used to compare proportions. For homogeneity of data
presentation, all values were expressed as the median, quar-
tiles and extremes, and outlier values were indicated. Differ-
ences and correlations with a two-tailed value of p<0.05
were considered statistically significant. The Prism 5 soft-
ware package (GraphPad, San Diego, CA, USA) was used
for statistical tests and graphical presentation of the data.
Results
Clinical and demographic characteristics
The characteristics of the children enrolled in the study
and the clinical outcomes during 3 and 6 months of cor-
ticosteroid treatment are summarized in Tables 1 and 2.and 6 months after inhaled corticosteroid therapy
nths 6 months Test p
ANOVA
23.6 99.2±18.4 p < 0.05*
16.8 86.3±18.3 p < 0.05*
17.0 77.9±19.8 p > 0.05
32.2 43.4±37.5 Kruskal-Wallis p>0.05
31.5 50.0±30.5
29.6 63.2±29.5
4.3%) 4/22 (18.2%) Chi-square
82.6%) 16/22 (72.7%) p<0.05
3.0%) 2/22 (9.1%)
(5%) 3/20 (15%) Chi-square
(35%) 10/20 (50.0%) p<0.05
(60%) 7/20 (35.0%)
(0%) 0/14 (0%) Chi-square
1.4%) 4/14 (28.6%) p>0.05
8.57%) 10/14 (71.4%)
st, mPA mild persistent asthma, MPA moderate persistent asthma,
6 m < before.
da Silva-Martins et al. Clinical and Translational Allergy 2013, 3:28 Page 5 of 12
http://www.ctajournal.com/content/3/1/28Children from the control group had the mean age 3 years
older than the asthmatic children (10.7 ± 2.10 years versus
7.6 ± 3.4 years; p=0.001, t test), but no difference was ob-
served based on gender between the children with or with-
out asthma (p=0.6, Chi-square test). To exclude a possible
influence of age as an independent confounding variable on
the results of phagocyte functions, the univariate correlation
between age and monocyte and neutrophil phagocytic indi-
ces and % NBT reduction for healthy control and asthmatic
children was tested. No correlation was observed between
age and these phagocyte functions (Spearman’s test, p>0.05).
Therefore, no adjustment of results of phagocyte functions
for age was done. Furthermore, previous observations had
shown that there are not differences among preschool chil-
dren, schoolchildren and adolescent phagocyte functions.
No statistically significant difference was observed be-
tween groups for leukocytes, except for eosinophils. The
median of the number of eosinophils in peripheral blood
was significantly higher in asthmatic children than healthy
control (245 for the control group and 460, 635, and 487
for mPA, MPA and SPA groups, respectively, before ICT;
p=0.003, ANOVA) (Table 1).
ACT and PEF showed the clinical improve after 3 and
6 months follow up (Tables 1 and 2).
In the 3 months evaluation, the phagocyte tests was done
in 50 children (n = 50), and in the 6 months evaluation,
the phagocyte tests of was done in 47 children (n = 47).Figure 1 In vitro evaluation of the phagocytic indices of monocytes (l
asthma (mPA), moderate persistent asthma (MPA) and severe persiste
using 2.5×105 yeast cells per well. For the top panels, sensitized yeasts wer
analyses showed that the median value of all groups of asthmatic children was lo
observed between the groups with mild, moderate and severe persistent asthma
as the median, quartile and extreme, and outlier values are marked.No difference was observed between the phagocytic
indices in children with different clinical severities of
persistent asthma
To determine whether the severity of persistent asthma
influenced the phagocytic capacity of monocytes and neu-
trophils, the phagocytic indices of monocytes and neutro-
phils from children with different severities of asthma were
compared. All groups of asthmatic children showed a
lower phagocytic index than the healthy control children;
however, no difference was observed between the children
with mild, moderate or severe persistent asthma (Kruskal-
Wallis test followed by Dunn’s method, p<0.01) (Figure 1).
Monocytes and neutrophils from children with asthma
showed less phagocytosis through pattern molecular
receptors, and treatment with ICS for 6 months was not
sufficient to normalize phagocytic function
To assess the influence of inhaled corticosteroids on phago-
cytosis, the phagocytic capacity of monocytes and neutro-
phils from children with different severities of asthma was
compared before and after corticosteroid treatment.
Using non-sensitized S. cerevisiae, the monocytes of chil-
dren with mild, moderate and severe persistent asthma
showed a lower phagocytic index than healthy children.
The median phagocytic index of the monocytes from chil-
dren with asthma from all groups prior to treatment was
significantly lower than that in the control healthy childreneft) and neutrophils (right) in individuals with mild persistent
nt asthma (SPA) before treatment and in normal control children
e used. For the bottom panels, non-sensitized yeasts were used. Statistical
wer than that of the healthy control children; however, no difference was
(Kruskal-Wallis test followed by the Dunn’s method). The data are expressed
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ficiency was caused by lower quantitative involvement of
phagocytes in phagocytosis when compared to the control
healthy children (p<0.05, Mann–Whitney test) (Figure 2B,
E, H), because there was no difference in the median num-
ber of phagocytosed S. cerevisiae per monocyte between
the control and asthmatic children (p>0.05, Mann–Whitney
test) (Figure 2A, D, G). Subsequent to the inhaled cortico-
steroid treatment of children with asthma, there were no
differences among the groups for phagocytic index, percent-
age of monocytes engaged in phagocytosis and the number
of yeast cells phagocytosed over six months of treatment
(Figure 2).
Similar results were observed for the neutrophils. Prior
to the inhaled corticosteroid treatment, the neutrophils
from children with mild, moderate and severe asthma alsoFigure 2 Influence of inhaled corticosteroid treatment on the phagoc
children with mild, moderate and severe persistent asthma before an
healthy controls using non-sensitized Saccharomyces cerevisiae. The d
outlier data are indicated. Top: average number of S. cerevisiae yeast cells in
monocytes engaged in phagocytosis (B, E, H); Bottom: monocyte phagocy
and in text.exhibited significantly lower phagocytic indices (p < 0.05,
Mann–Whitney test; Figure 3C, F, I) and lower propor-
tions of cells involved in phagocytosis (p < 0.05, Mann-
Whiney test; Figure 3B, E, H) than the neutrophils
from control healthy children for non-sensitized yeast
cells (Figure 3). ICS therapy for 3 and 6 months did not
modify phagocytosis by the neutrophils (Figure 3).
Monocytes and neutrophils from children with asthma
showed less phagocytosis of opsonized yeast cells via
complement and immunoglobulin receptors, and
treatment with inhaled corticosteroids (ICS) for 6 months
was not sufficient to normalize phagocyte function
Using sensitized S. cerevisiae, the monocytes and neutrophils
from children with mild, moderate and severe persistent
asthma also showed lower phagocytic indices than theytic capacity of monocytes via pattern-recognition receptors in
d during the 3rd and 6th months of treatment compared to
ata are expressed as the median, quartile and extreme values. The
gested by phagocytosing monocytes (A, D, G); Middle: percentage of
tic index (C, F, I). The statistical differences are marked in the graphics
Figure 3 Influence of inhaled corticosteroid treatment on the phagocytic capacity of neutrophils via pattern-recognition receptors in
children with mild, moderate and severe persistent asthma before and during the 3rd and 6th months of treatment compared to
healthy controls using non-sensitized Saccharomyces cerevisiae. The data are expressed as the median, quartile and extreme values. The
outlier data are indicated. Top: average number of S. cerevisiae yeast cells ingested by phagocytosing neutrophils (A, D, G); Middle: percentage of
neutrophils engaged in phagocytosis (B, E, H); Bottom: neutrophil phagocytic index (C, F, I). The statistical differences are marked in the graphics
and in text.
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cytes and neutrophils from children with asthma from all
groups prior to treatment was significantly lower than the
healthy control children (p<0.05, Mann–Whitney test;
Figure 4C, F, I). This result differed from that obtained
using the non-sensitized yeasts. The decrease in monocyte
and neutrophil phagocytic index was caused by both the
lower quantitative involvement of the phagocytes in pha-
gocytosis when compared to the healthy control children
(p<0.05, Mann–Whitney test; Figure 4B, E, H; Figure 5B,
E, H), and the smaller number of particles phagocytosed
per monocyte or neutrophil (p > 0.05, Mann–Whitney
test, Figure 4A, D, G; Figure 5A, D, G). Moreover, ICS
therapy for 6 months was not able to modify the phago-
cytic index, the percentage of monocytes or neutrophilsengaged in phagocytosis or the number of phagocytosed
yeast (Figures 4 and 5).
Influence of inhaled corticosteroids on superoxide anion
production
The difference between the control and asthmatic children
was statistically significant only for the children with mild
persistent asthma (Figure 6A, D). When the % reduction of
NBT was assessed either with (p<0.02, Mann–Whitney test,
Figure 6A) or without stimulation (p=0.01, Mann–Whitney
test, Figure 6D), the capacity to produce superoxide
anions was decreased in the asthmatic children before
treatment. Treatment with inhaled corticosteroids dif-
ferentially influenced the production of this oxygen
radical. When assessed without stimuli, there was an
Figure 4 Influence of inhaled corticosteroid treatment on the phagocytic capacity of monocytes via opsonin receptors in children with
mild, moderate and severe persistent asthma before and during the 3rd and 6th months of treatment compared to healthy controls
using sensitized Saccharomyces cerevisiae. The data are expressed as the median, quartile and extreme values. The outlier data are indicated.
Top: average number of S. cerevisiae yeast cells ingested by phagocytosing monocytes (A, D, G); Middle: percentage of monocytes engaged in
phagocytosis (B, E, H); Bottom: monocyte phagocytic index (C, F, I). The statistical differences are marked in the graphics and in text.
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ment (p<0.05, Kruskal-Wallis test followed by Dunn’s
method, Figure 6D). However, when the % NBT reduc-
tion was assessed after phagocytosis stimulation, there
was decreased production of superoxide anions after 3
and 6 m of follow-up (p<0.05, Kruskal-Wallis test
followed by Dunn’s method) (Figure 6A).
Discussion
This prospective study evaluated for the first time the in-
fluence of 3 and 6 months of treatment with inhaled corti-
costeroids on the neutrophil and monocyte functions of
asthmatic children. Our data showed that 6 months of ICS
was not sufficient to return the decreased phagocyte func-
tions to normal in the asthmatic children. Although
6 months of treatment caused some improvement in the
clinical parameters, such as an increase in peak expiratoryflow, and a significant increase in percentage of children
with mild and moderate persistent asthma showing ACT >
25 and ACT = 20–24, (Table 2), no concomitant recovery
of phagocyte function was observed.
Our data showed that the phagocytic capacity of mono-
cytes and neutrophils in children with mild, moderate and
severe persistent asthma was lower than in the healthy
control children. A significant decrease in phagocytosis by
monocytes and neutrophils [19,20], bronchial macro-
phages [21] and alveolar macrophages [11] has also been
shown in asthmatic individuals.
Our data demonstrated that the severity of asthma did
not influence the immunodeficiency in phagocytes. The
phagocytic indices of the neutrophils and monocytes from
the children with mild, moderate or severe persistent
asthma were decreased, and there were no differences
among these groups (Figure 1). Our data differed from those
Figure 5 Influence of inhaled corticosteroid treatment on the phagocytic capacity of neutrophils via opsonin receptors in children
with mild, moderate and severe persistent asthma before and during the 3rd and 6th months of treatment compared to healthy
controls using sensitized Saccharomyces cerevisiae. The data are expressed as the median, quartile and extreme values. The outlier data are
indicated. Top: average number of S. cerevisiae yeast cells ingested by phagocytosing neutrophils (A, D, G); Middle: percentage of neutrophils
engaged in phagocytosis (B, E, H); Bottom: neutrophil phagocytic index (C, F, I). The statistical differences are marked in the graphics and in text.
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severe asthma patients. However, Alexis et al. [21] also
showed decreased phagocytosis in mild asthma patients,
whereas Lay et al. [22] observed increased phagocytosis by
macrophages obtained from the sputum of asthma patients.
The differences between our observations and those of other
researchers who have assessed phagocytosis in asthma are
most likely the result of the following factors: differences in
the clinical form of the disease, the severity of the disease,
the age of individuals, the treatment used, the stimuli used,
the source of phagocytes tested, the cell type assessed, and
genetic differences between individuals [11,19-22].
The deficiency in phagocytosis was evident when phago-
cytosis was assessed either through pathogen associated
molecular pattern receptors (non-sensitized) or through
complement and antibody receptors (sensitized). To be
able to phagocytose, the phagocyte needs to move toward
the S. cerevisiae and ingest the particle. Because thereduction in phagocytosis was attributable to the de-
creased quantitative involvement of the phagocytes in
phagocytosis, it is possible that phagocytes in asthmatic
children had decreased capacity to move toward the yeast.
In fact, it was previously shown that β2-agonists and glu-
cocorticoids, which are commonly used for the treatment
of obstructive lung diseases, influence chemokine release
and receptor sensitivity and, consequently, the chemotaxis
of these cells [23].
When sensitized phagocytosis through FcγR and comple-
ment receptors was assessed, the deficiency was evidenced
as both to the decreased quantitative involvement of the
phagocytes in phagocytosis and the decreased number of
yeast cells phagocytosed. The reasons for this effect are not
clear; however, one possible explanation is a decrease in the
expression of receptors for complement and/or FcγR in the
membranes of the monocytes and neutrophils from asthma
patients. Alexis et al. [19] found a significant correlation
Figure 6 Comparison of phagocyte production of toxic oxygen radical molecules assessed as the per cent reduction of nitro blue
tetrazolium among the groups with mild, moderate and severe persistent asthma and healthy control children. In A, B, C: under
stimulation. In D, E, F: baseline. The data are expressed as the median, quartile and extreme values. The outlier data are indicated. The statistical
differences are marked in the graphics and in text.
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http://www.ctajournal.com/content/3/1/28between the expression of CD64 (FcγR) and phagocytosis
by bronchial macrophages from asthmatic individuals and
the reduced expression of CD11b, a component of the CR3
receptor, and phagocytosis in sputum and in neutrophils
and monocytes from asthmatics.
Although there was clinical improvement in asthma
with corticosteroid therapy, we can hypothesize that the
effect of the drug on phagocytes decreasing the phago-
cytosis may have contributed to the insufficient recovery
of phagocytosis after six months of clinical follow-up. In
fact, corticosteroids decrease phagocytosis by monocytes
and the production of inflammatory cytokines [3,13].
Corticosteroids also increase the production of IL-10, a
cytokine that deactivates monocytes [3,5]. Therefore, it
is possible that phagocytosis did not return to normal
because of the action exerted by the corticosteroids on
the phagocytes. Another possibility to explain this lack
of response of phagocytes to ICT by us observed might
be that the insufficient recovery of immune alterations
remained downmodulating phagocyte function.
Superoxide anion production, which was assessed as
the per cent reduction of nitro blue tetrazolium, by
phagocytes from asthmatic and control children was sta-
tistically decreased only for children with mild persistent
asthma. The response to ICS after 6 months of treat-
ment was different when assessed at baseline or after
stimulation. Inhaled corticosteroids increased the percent NBT reduction only when assessed without sti-
mulation; however, these values were to the values of
healthy, normal children, they did not exceed the values
observed in normal children. However, when superoxide
anion production was evaluated after stimulation with
sensitized S. cerevisiae, there was a decrease in super-
oxide anion production. It is possible that decreased
phagocytosis may have played a role in the decreased
superoxide anion production by these cells.
Generation of radical oxygen species occurs through
several enzymatic pathways or chemical process that are
essential in many physiological reactions such as killing
invading pathogens, and takes place in every cell. How-
ever, increased levels of ROS can produce harmful pa-
thophysiological disorders that damage DNA, lipids,
proteins, and carbohydrates, leading to enhanced inflam-
matory response [24]. Oxidative stress has been proven to
affect smooth muscle contraction, induce airway hyper-
responsiveness, and increase mucus secretion, and exces-
sive ROS production can trigger key alterations, leading to
an antioxidant-oxidant imbalance that has been shown in
patients with asthma and differ significantly according to
severity of the disease [24-26]. It was also observed that
resting or stimulated phagocytes may produce differently
reactive oxygen species that depends on the disease form
[27]. Predominance of enhancement of ROS has been ob-
served in asthma [25-27]. The differences between our
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ROS in asthma are most likely the result of the type of
ROS evaluated, the cell type assessed and differences in
the clinical form and severity of the disease.
Influence of treatment with corticoid has been also evalu-
ated. It was observed that budesonide reduced the oxidative
stress in the in guinea pig [28] and ICT was able to influ-
ence the production of NADP oxidase in a dose dependent
manner [29]. Treatment with glucocorticosteroids as anti-
oxidants has been suggested, based in its antioxidants prop-
erties [30]. We only observed influence of ICT in mild
persistent asthma. A possible explanation by the different
response observed by us is the type of ROS analyzed and
the cell tested.
Oxidative injury leads to increased lipid peroxidation, in-
creased airway reactivity and secretions, production of
chemoattractant molecules, and increased vascular perme-
ability [31-33], which collectively lead to the augmentation
of the existing inflammation that is a hallmark of asthma.
Therefore, lower oxygen radical production in asthma may
contribute to the decreased immunopathogenesis by these
molecules in asthma. On the other hand, a lower produc-
tion of superoxide anions can lead to immunodeficiency
and may hinder the immune defense against infectious
agents.
Although corticosteroids are considered the first-line
drugs for asthma therapy, the number of children that
meet the clinical control evaluated by ACT (>25) in chil-
dren that were followed-up for 6 m in this study was
small. Significant variability in the response to inhaled
corticosteroids for persistent asthma has been shown
[34], and uncontrolled asthma occurs in more than 50%
of children who receive treatment with low-dose inhaled
corticosteroids [35]. It is possible that this lower clinical
response occurred because there was a high percentage
of moderate and severe persistent asthma among the
assessed children. Furthermore, the children were trea-
ted at home, and although adherence to treatment was
encouraged in all clinical evaluation, there is no assur-
ance regarding the regular use of corticosteroids during
the follow-up period. This uncertainty is a limitation of
our study. The lower age of asthmatic children than
healthy control children was also a limitation, however,
we had already showed that there are not differences in
phagocytosis between children higher 2 years old [16].
Some children received different ICS (budesonide or
fluticasone) that is a limitation of this study. Another
possible limitation of our study is the fact that phagocyt-
osis was assessed in phagocytes obtained from peripheral
blood and not from induced-sputum or bronchoalveolar
lavage in order to evaluate directly the effects of disease
and treatment on the phagocytic function at the local
level. However, asthma is a systemic disease showing sev-
eral cytokines and other molecules enhanced in peripheralblood that may influence functions of cells of immune sys-
tem and phagocytosis and might be influenced by corti-
coid treatment as we observed in this paper. In support to
this consideration, morphological changes in eosinophils
obtained from peripheral blood markedly correlate with
the disease and may indicate the clinical severity of the
acute exacerbation [36], corroborating that blood cells
may also be influenced by the immune response occurring
in asthmatic individuals. Furthermore, sputum induction
can be challenging for young children [37], and the in-
fluence on phagocytosis of mucus [38], enzymes [39] and
microorganisms [40] presents in sputum couldn’t be ex-
cluded, in addition to the ethical limitation to evaluate
phagocytosis in phagocytes from bronchoalveolar lavage.
Conclusions
Our findings may broaden the understanding of the in-
fluence of inhaled corticosteroids on phagocyte func-
tions. Our data showed that asthmatic children followed
up for 6 months in treatment with ICT didn’t modify
decreased phagocytosis. However, the baseline produc-
tion of superoxide anions by phagocytes was normalized.
Because phagocytes actively participate in both the le-
sion and the defense of the lung in asthma, it is possible
that the result of these opposing effects was beneficial to
treated patients because there was some clinical im-
provement. Furthermore, the reduction in lesions caused
by oxygen radicals may have been beneficial to the
treated children.
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